Australia markets closed

Alterity Therapeutics Ltd (PBN.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
0.00200.0000 (0.00%)
At close: 08:08AM CET
Full screen
Previous close0.0020
Open0.0020
Bid0.0020 x 0
Ask0.0035 x 0
Day's range0.0020 - 0.0020
52-week range0.0015 - 0.0125
Volume750,000
Avg. volume17,177
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

    – Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2 Clinical Trial – MELBOURNE, Australia and SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that thr

  • GlobeNewswire

    Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

    - ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its second review of trial data and recommended the ATH

  • GlobeNewswire

    Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

    MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the ShareCafe Hidden Gems webinar on the following dates/times: AUSTRALIA PARTICIPANTS:Date: Friday, 2 February 2024Time: 12:30 p.m. AEDT / 9:30 a.m. AWS